

# Bicycle

## Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Jan. 9, 2025-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle<sup>®</sup>) technology, today announced that management will participate at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT.

A live webcast of the presentation will be accessible from the Investor section of the company's website at [www.bicycletherapeutics.com](http://www.bicycletherapeutics.com). A replay of the webcast will be archived and available following the event.

### About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle<sup>®</sup> molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle<sup>®</sup> Toxin Conjugate (BTC<sup>®</sup>) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist<sup>®</sup> (Bicycle TICA<sup>®</sup>) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC<sup>®</sup>) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle<sup>®</sup> technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit [www.bicycletherapeutics.com](http://www.bicycletherapeutics.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20250109465188/en/>

### Investors:

Stephanie Yao  
SVP, Investor Relations and Corporate Communications  
[stephanie.yao@bicycletx.com](mailto:stephanie.yao@bicycletx.com)  
857-523-8544

Matthew DeYoung  
Argot Partners  
[ir@bicycletx.com](mailto:ir@bicycletx.com)  
212-600-1902

### Media:

Jim O'Connell  
Weber Shandwick  
[media@bicycletx.com](mailto:media@bicycletx.com)  
312-988-2343

Source: Bicycle Therapeutics plc